HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case

This article was originally published in The Tan Sheet

Executive Summary

This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation

You may also be interested in...



Supreme Court Ruling In Wyeth Case May Make FDA More Cautious

How the U.S. Supreme Court rules in Wyeth v. Levine could limit the number of product liability suits brought against drug companies

Waxman Report Showing FDA Pre-emption Split May Alter Legal Debate

A report from influential House leader Henry Waxman exposes a rift between senior FDA staff and the agency's Office of Chief Counsel that could help the plaintiff in the FDA pre-emption case that has reached the Supreme Court

Pre-Emption Battle Looms In Supreme Court As FDA Finalizes Labeling Rule

FDA's final rule on sponsors' obligations to update their labels alters the definition of "newly acquired information" from the proposed rule while leaving the remainder intact. The change could be a boon to industry, but a slap to Democrats who had called for the rule's withdrawal

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS137121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel